Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04743141
Status:
RECRUITING
Last Update Posted:
2024-07-01
First Post:
2021-02-04
Brief Title:
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 3 Multicenter Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With or Without Aura in Children and Adolescents 6 to 18 Years of Age
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents 6 to 18 years of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-003761-18 | REGISTRY | CTIS EU | None |
| C4951003 | OTHER | None | None |